Penumbra
About: Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. It operates as one reportable segment and its business activity consists of the design, development, manufacturing and marketing of inventive medical products.
Employees: 4,500
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
502% more call options, than puts
Call options by funds: $95.8M | Put options by funds: $15.9M
136% more first-time investments, than exits
New positions opened: 92 | Existing positions closed: 39
50% more funds holding in top 10
Funds holding in top 10: 4 [Q4 2024] → 6 (+2) [Q1 2025]
13% more funds holding
Funds holding: 367 [Q4 2024] → 415 (+48) [Q1 2025]
11% more capital invested
Capital invested by funds: $8.3B [Q4 2024] → $9.24B (+$945M) [Q1 2025]
9% more repeat investments, than reductions
Existing positions increased: 141 | Existing positions reduced: 129
1.28% less ownership
Funds ownership: 90.97% [Q4 2024] → 89.69% (-1.28%) [Q1 2025]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
6 analyst ratings
RBC Capital Shagun Singh | 33%upside $330 | Outperform Maintained | 24 Apr 2025 |
UBS Priya Sachdeva | 33%upside $330 | Buy Maintained | 24 Apr 2025 |
Truist Securities David Rescott | 33%upside $330 | Buy Maintained | 24 Apr 2025 |
Stifel Mathew Blackman | 28%upside $318 | Buy Maintained | 24 Apr 2025 |
Wells Fargo Larry Biegelsen | 27%upside $315 | Overweight Maintained | 24 Apr 2025 |
Financial journalist opinion
Based on 7 articles about PEN published over the past 30 days
